FDA Authorizes Clinical Trials Evaluating Lynch Regenerative Medicine’s rhPDGF-BB for Facial Skin Quality and Infraorbital Hollows
Lynch Regenerative Medicine (LRM) announced that the FDA has authorized two investigator-initiated investigational new drug (IND) applications to study injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) for aesthetic indications. The studies will evaluate the treatment’s potential use for facial skin quality and infraorbital hollows, commonly known as under-eye hollows.
According to the company, one trial will evaluate rhPDGF-BB for improving facial skin quality, while the second will study the treatment in patients with infraorbital hollows. Both studies are expected to be conducted by independent investigators under FDA-authorized INDs.
rhPDGF-BB is a recombinant growth factor that has previously been used in other regenerative medicine applications. The newly authorized studies are intended to generate data on its potential use in aesthetic medicine, an area where interest in regenerative and biologic treatments has continued to grow.
The announcement represents an early clinical development step rather than an FDA approval. The studies are designed to evaluate safety and efficacy and will help determine whether further development for aesthetic indications is warranted.
